DUBLIN--(BUSINESS WIRE)--The "CAR T-Cell therapy Market By Drug type, By Indication, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The CAR T-cell therapy market was valued at $1,709.00 million in 2021, and is estimated to reach $6,093.10 million by 2031, growing at a CAGR of 13.5% from 2022 to 2031.

Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer.

T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.

The CAR T-cell therapy market will show significant market growth during the forecast period owing to rise in prevalence of cancer, rise in demand for ideal therapeutics for treatment of cancer, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries.

However, higher cost of treatment, and stringent government regulation for approval of these therapeutics are expected to hamper the market growth.

Furthermore, promising drugs in pipeline, expected approval of newer CART therapeutics, rise in number of target population with lack of ideal treatment, and surge in awareness regarding CART therapies are expected to significantly drive the market growth during the forecast period. In addition, technological advancements, launch of various products, and strategies among the key players such as acquisition, collaboration, and agreement drive the CAR T-cell therapy market growth.

The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.

The CAR T-cell therapy market is studied across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Key Benefits

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By End user

• Hospitals
• Cancer Treatment Centers

By Drug type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By Region

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Rest of Asia-Pacific
• LAMEA
• Latin America
• Middle East And Africa

Key Market Players

• Autolus Therapeutics
• Bluebird bio, Inc.
• Bristol-Myers Squibb
• Caribou Biosciences, Inc.
• Cartesian Therapeutics, Inc.
• Celgene Corporation
• Cellectis
• Celyad Oncology
• Gilead Sciences, Inc. (Kite Pharma Inc.)
• Intellia Therapeutics
• Juno Therapeutics, Inc.
• Merck & Co., Inc.
• Miltenyi Biotech
• Novartis AG
• Pfizer, Inc.
• Sorrento Therapeutics, Inc.

For more information about this report visit

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900